Enhancing Blood Fluidity and Physiological Markers in Early Stage Alzheimer’s Disease Using Biophoton Generators: A Case Study

Authors

  • Ya Hu First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA Author
  • Leon Chien First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA Author
  • Helen Y Gu First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA Author
  • James Z Liu First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA Author

DOI:

https://doi.org/10.47363/JNRRR/2025(7)223

Keywords:

Alzheimer’s Disease, Blood Fluidity, Biophoton Therapy, Microcirculation, Cellular Morphology, Oxygen Saturation

Abstract

Background: Impaired blood fluidity and microcirculation are increasingly recognized as contributors to the pathophysiology of Alzheimer’s disease (AD). This study investigates the effect of strong biophoton generators on blood quality, oxygenation, and cellular morphology in a patient with early-stage AD.

Methods: A 59-year-old female with clinically diagnosed early-stage AD was exposed to four biophoton generators emitting coherent biophysical fields for ≥8 hours/day over 4 weeks. Blood samples were analyzed under a dark-field microscope at Baseline, Day 3, Day 5, Day 13, Day 18, and Day 27. Physiological markers assessed included blood viscosity, oxygen saturation, lipid profile, and cellular morphology.

Results: By Day 3, blood became cleaner with reduced cell aggregation and increased oxygenation. By Day 5, further improvements in morphology and immune activation were observed. Day 13 and Day 18, showed reduced systemic pain and better sleep initiation without hormonal support. By Day 27, the patient displayed stabilized cell morphology, improved metabolism, and reduced dependence on medications.

Conclusion: Biophoton therapy demonstrated a measurable improvement in blood fluidity, oxygen delivery, and systemic homeostasis. These changes may support neurological stabilization and pain reduction, offering a novel adjunctive approach for early-stage Alzheimer’s disease. Further controlled studies are warranted.

Author Biographies

  • Ya Hu, First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

    First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

  • Leon Chien, First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

    First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

  • Helen Y Gu, First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

    First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

  • James Z Liu, First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

    First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA

Downloads

Published

2025-07-21

Issue

Vol. 7 No. 7 (2025): Volume 7 Issue 7

Section

Articles